Pearson

03/05/21 -"We have slightly raised our target price following what we judge as an encouraging Q1 21 trading update (please refer to our 26/04/2021 Latest). Going forward, vaccination, which has been strong in ..."

PDF page sample
Pages
53
Language
English
Published on
03/05/21
Download
You may also be interested by these reports :
02/12/25
Following the publication of the Q3 results, we have consolidated ProSieben for 2026-27. ProSieben, now 75% owned, will be included in MFE’s accounts ...
21/11/25
CTS Eventim released very good Q3 figures, which notably surpassed market consensus expectations on profitability, and reiterated its guidance for ...
18/11/25
Your obvious AI quality call (II)
17/11/25
Informa unveiled an attractively refined guidance for the 2025-2028 period for its CMD, which is broadly in line with our estimates. There are no ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO